Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

2
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (0)

Searched Name

Mezavant

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Ozanimod (Zeposia) for ulcerative colitis. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2021;63:147-151. [PMID: 34550962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023] Abstract Collapse Key Words Amgevita Apriso Asacol Avsola Azasan Azulfidine Colazal Cortiment Delzicol Dipentum Entyvio Hadlima Hulio Humira Hyrimoz Idacio Imuran Inflectra Lialda Mezavant Pentasa Purixan Rayos Remicade Renflexis Salazopyrin Salofalk Simponi Stelara TNF inhibitors Uceris Xeljanz Zeposia adalimumab adverse effects aminosalicylates azathioprine balsalazide budesonide corticosteroids dosage drug interactions efficacy golimumab infliximab lactation mercaptopurine mesalamine mesalazine olsalazine ozanimod prednisone pregnancy safety sulfasalazine tofacitinib ulcerative colitis ustekinumab vedolizumab Collapse MESH Headings Colitis, Ulcerative/drug therapy Double-Blind Method Drug Approval Drug Interactions Gastrointestinal Agents/administration & dosage Gastrointestinal Agents/adverse effects Gastrointestinal Agents/therapeutic use Humans Indans/administration & dosage Indans/adverse effects Indans/therapeutic use Oxadiazoles/administration & dosage Oxadiazoles/adverse effects Oxadiazoles/therapeutic use Randomized Controlled Trials as Topic Severity of Illness Index United States United States Food and Drug Administration Collapse Grants Collapse
2	Drugs for inflammatory bowel disease. THE MEDICAL LETTER ON DRUGS AND THERAPEUTICS 2018;60:107-114. [PMID: 30036352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023] Abstract Collapse Key Words Aminosalicylates Antibiotics Apriso Asacol Azasan Azulfidine Betnesol Canasa Cimzia Colazal Colocort Cortenema Corticosteroids Cortifoam Cortiment Crohn's disease Cyclosporine Delzicol Dipentum Entocort Entyvio Giazo Hadima Humira Imuran Inflectra Integrin Receptor Antagonists Interleukin (Il)-12 and -23 Antagonist Ixifi JAK Inhibitor Janus Kinase Inhibitor Lialda Methotrexate Metoject Mezavant Otrexup Pentasa Purixan Rasuvo Rayos Remicade Renflexis Rowasa Salazopyrin Salofalk Sandimmune Simponi Stelara TNF Inhibitors TNF inhibitors Thiopurines Tysabri Uceris VSL Xeljanz adalimumab adverse effects aminosalicylates antibacterials azathioprine balsalazide betamethasone budesonide certolizumab corticosteroids cyclosporine dosage drug interactions efficacy golimumab hydrocortisone inflammatory bowel disease infliximab mercaptopurine mesalamine mesalazine methotrexate natalizumab olsalazine prednisone probiotics sulfasalazine tofacitinib ulcerative colitis ustekinumab vedolizumab Collapse MESH Headings Gastrointestinal Agents/administration & dosage Gastrointestinal Agents/adverse effects Gastrointestinal Agents/therapeutic use Humans Immunosuppressive Agents/administration & dosage Immunosuppressive Agents/adverse effects Immunosuppressive Agents/therapeutic use Inflammatory Bowel Diseases/drug therapy Interleukins/antagonists & inhibitors Janus Kinase Inhibitors/therapeutic use Tumor Necrosis Factor-alpha/antagonists & inhibitors Collapse Grants Collapse